

Atty. Dkt. No. 078853-0302

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for treating or preventing cardiovascular or cerebrovascular disease in a mammal, comprising administering an agent that alters the activity or concentration of an enzyme in an amount effective to treat or prevent cardiovascular or cerebrovascular disease in a mammal, wherein said enzyme catalyzes a reaction that produces or degrades a sphingolipid or a sphingolipid metabolite; and

wherein said agent is not an aminoglycoside.

2. (Currently amended) A method for treating or preventing undesirable post-ischemic events in an animal, comprising administering thereto an agent that alters the activity or concentration of an enzyme in an amount effective to treat or prevent undesirable post-ischemic events in a mammal, wherein said enzyme catalyzes a reaction that produces or degrades a sphingolipid or a sphingolipid metabolite; and

wherein the agent is not an aminoglycoside.

3. (Original) The method of claim 2 wherein said undesirable post-ischemic events occur in the heart.

4. (Original) The method of claim 2 wherein said undesirable post-ischemic events occur in the brain.

5. (Currently amended) A method for treating or preventing cardiovascular disease in a human, comprising administering an agent that alters the activity or concentration of an enzyme in an amount effective to treat or prevent cardiovascular disease in a human, wherein said enzyme catalyzes a reaction that produces or degrades a sphingolipid or a sphingolipid metabolite; and

wherein the agent is not an aminoglycoside.

Atty. Dkt. No. 078853-0302

6. (Currently amended) The method of claim 5, wherein said sphingolipid or a sphingolipid metabolite is selected from the group consisting of sphingomyelin, sphingosine, S-1-P sphingosine-1-phosphate, ceramide, SPG sphingosylphosphorylcholine, 3-ketosphinganine, galactosylceramide and dihydroceramide.

7. (Currently amended) The method of claim 5, wherein said enzyme is selected from the group consisting of SM sphingomyelin synthase, SM sphingomyelin deacylase, SMase sphingomyelinase, ceramidase, S-1-P-phosphatase sphingosine-1-phosphate phosphatase, SPH sphingosine kinase, Ger Ceramide synthase, S-1-P sphingosine-1-phosphate lyase, cerebrosidase, Ger 1-P Ceramide-1-phosphate phosphatase, Ger Ceramide kinase, SM sphingomyelin deacylase, SPT serine palmitoyltransferase, NADPH-dependent reductase.

8. (Currently amended) The method claim 5, wherein said enzyme is SMase sphingomyelinase

9-14. (Cancelled)

15. (Original) The method of claim 1, wherein said disease is a cardiovascular disease.

16. (Original) The method of claim 15, wherein said cardiovascular disease is a cardiac disease.

17. (Original) The method of claim 16, wherein said cardiac disease is selected from the group consisting of myocardial ischemia; acute myocardial infarction (AMI); coronary artery disease (CAD); acute coronary syndrome (ACS); cardiac cell and tissue damage that may occur during or as a consequence of percutaneous revascularization (coronary angioplasty) with or without stenting; coronary bypass grafting (CABG) or other surgical or medical procedures or therapies that may cause ischemic or ischemic/ reperfusion damage; and cardiovascular trauma.

Atty. Dkt. No. 078853-0302

18. (Cancelled)

19. (Currently amended) A method for treating or preventing cardiovascular or cerebrovascular disease, comprising administering the a pharmaceutical composition of claim 18 comprising an agent in an amount effective to modulate the activity of an enzyme that catalyzes a reaction that produces or degrades a sphingolipid or a sphingolipid metabolite; wherein the agent is not an aminoglycoside.

20. (Currently Amended) A formulation comprising an agent which will, when provided to an animal in need thereof, alter the activity or concentration of an enzyme that produces or degrades a sphingolipid or a sphingolipid metabolite to a degree necessary to achieve a therapeutic effect, wherein said agent is not an aminoglycoside.

21. (New) The method of claim 7 wherein the enzyme is sphingomyelinase and the agent is selected from the group consisting of: sphingomyelin derivatives, scyphostatins, manumycin, quinones, ubiquinol, ubiquinones, sphingomyelin methylene, anthracyclines, carnitine, desipramine, alutenusin, SR3357, adriamycins, and roselipins.

22. (New) The method of claim 7 wherein the enzyme is sphingomyelinase, and the agent is selected from the group consisting of: anti-oxidants, ascorbate, alpha-tocopherol, glutathione, desipramine, and DTT.

23. (New) The method of claim 7 wherein the enzyme is sphingosine kinase and the agent is selected from the group consisting of: N,N-dimethylsphingosine, D-threo-dihydrosphingosine, and a sphingoid base.

24. (New) The method of claim 7 wherein the enzyme is ceramidase and the agent is selected from the group consisting of: N-acetylsphingosine, (1S, 2R)-D-erythro-2-(N-myristoylamino-1-phenyl-1-propanol, (1S, 2R)-L-erythro-2-(N-myristoylamino-1-phenyl-1-propanol, and N-oleoyl-ethanolamine.

Atty. Dkt. No. 078853-0302

25. (New) The method of claim 7 wherein the enzyme is ceramide synthase, and the agent is selected from the group consisting of: Fumonisin B1, an alternaria toxin, a viridifungin, and an astralifungin.

26. (New) The method of claim 7 wherein the enzyme is ceramide-1-phosphate phosphatase, and the agent is selected from the group consisting of: sodium fluoride, propranolol, phenylglyoxal, and N-ethylmaleimide.

27. (New) The method of claim 7 wherein the enzyme is ceramide-1-phosphate phosphatase, and the agent is a cyclopropene ceramide.

28. (New) The method of claim 7 wherein the enzyme is serine palmitoyl transferase, and the agent is selected from the group consisting of: lipoxamicin, a sphingofungin, an isaria sinclairii compound, L-cycloserine, beta-chloro-L-alanine, myriocin, and thermozytocidin.